| 초록 |
Background: ABO-incompatible living kidney transplantation (ABO-iLKT) has been performed to compensate for the shortage of organ donors. Some reports noted that the titers of anti-ABO blood-type IgG antibody before plasma exchange and post-transplant were correlated well with graft survival in ABO-i LKT. After the immunosuppressive regimen introduced using tacrolimus (TAC), mycophenolate mofetil (MMF) and steroid, lower levels of ABO blood type antibody titers have reported in patients with ABO-iLKT. Enteric-coated mycophenolate sodium (EC-MPS) was known to have similar efficacy and safety of compared with mycophenolate mofetil (MMF). So we compared post- transplant anti-ABO blood type antibody titers between using EC-MPS and MMF in patients with ABO-iLKT.
Methods: Twenty one subjects performed ABO-iLKT were included in this study. Rituximab, plasma exchange, TAC, MMF, steroid were used before transplantation. 13 subjects’ immunosuppressive regimens were changed MMF to EC-MPS after transplant. Others continued to use MMF. The titers of anti-ABO blood-type IgG and IgM antibody were measured 3, 6, 9, 12 month after transplantation in each group. Antibody titers were presented as 2x and Mann Whitney U test were performed with ∆ x. P values under 0.05 were considered statistically significant.
Results: The P values of anti-ABO IgG were 0.31, 0.37, 0.07, 0.17 at 3, 6, 9, 12 month after ABO-iLKT. And The p values of anti-ABO IgM were 0.14, 0.78, 0.67, 0.27 at 3, 6, 9, 12 month after tansplant. There was no statistically significant difference of anti-ABO IgG and IgM titers between using EC-MPS and MMF.
Conclusion: The use of MMF and EC-MPS may not have a difference in ABO antibody titers after ABO-ILKT. |